Avery Dennison Medical Solutions, a division of Avery Dennison Corp., has announced the completion of a license agreement around Quick-Med’s NIMBUS® technology. The announcement comes after the successful development of a new antimicrobial adhesive featuring NIMBUS technology that can be used for medical applications including surgical, wound care, and vascular access. The performance of the antimicrobial adhesive has demonstrated efficacy across multiple organisms, even in the presence of large amounts of serum and body fluids.

“We are advancing our antimicrobial technology platform to provide innovative solutions that answer the needs of medical device providers and patients worldwide,” said Howard Kelly, vice president and general manager of Avery Dennison Medical Solutions. “The success of our partnership with Quick-Med is a key component of our progress in this segment. We look forward to continued growth now that the license agreement is in place.”

Under a joint development agreement initiated in April 2009, the two companies collaborated to incorporate Quick-Med’s proprietary NIMBUS antimicrobial technology into Avery Dennison Medical Solutions’ adhesive technologies for medical device applications. NIMBUS is non-toxic, non-leaching, and non-depleting, and is designed to eliminate the risk of bacterial resistance issues.

“Successful development of the antimicrobial adhesive and completion of the license agreement with Avery Dennison Medical Solutions, an industry leader and innovator, further validates the potential of Quick-Med’s technologies for a range of applications,” said J. Ladd Greeno, CEO of Quick-Med Technologies. “This valuable partnership will continue to leverage the combination of their inventive adhesive technologies with our highly effective, non-toxic, long-lasting, non-leaching and affordable antimicrobial protection for the multi-billion dollar global medical adhesives market.”

For more information, visit www.quickmedtech.com or www.averydennison.com.